Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study

Abstract Background To explore the trajectory of, and factors contributing to, achievement of individual criteria of minimal disease activity (MDA) in patients with active psoriatic arthritis (PsA) treated with guselkumab. Methods The Phase 3, randomized, placebo-controlled DISCOVER-2 study enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Laura C. Coates, Proton Rahman, Philip J. Mease, May Shawi, Emmanouil Rampakakis, Alexa P. Kollmeier, Xie L. Xu, Soumya D. Chakravarty, Iain B. McInnes, Lai-Shan Tam
Formato: Artículo
Lenguaje:English
Publicado: BMC 2024-02-01
Colección:BMC Rheumatology
Materias:
Psoriatic arthritis
Biologics
Guselkumab
Minimal disease activity
Acceso en línea:https://doi.org/10.1186/s41927-024-00375-w

Internet

https://doi.org/10.1186/s41927-024-00375-w

Ejemplares similares